Age, Biography and Wiki
Julia Levy (Julia Coppens) was born on 13 May, 1934 in Singapore, is a Canadian microbiologist, immunologist, educator and entrepreneur. Discover Julia Levy's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is she in this year and how she spends money? Also learn how she earned most of networth at the age of 89 years old?
| Popular As |
Julia Coppens |
| Occupation |
N/A |
| Age |
89 years old |
| Zodiac Sign |
Taurus |
| Born |
13 May, 1934 |
| Birthday |
13 May |
| Birthplace |
Singapore |
| Nationality |
Singapore
|
We recommend you to check the complete list of Famous People born on 13 May.
She is a member of famous educator with the age 89 years old group.
Julia Levy Height, Weight & Measurements
At 89 years old, Julia Levy height not available right now. We will update Julia Levy's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
She is currently single. She is not dating anyone. We don't have much information about She's past relationship and any previous engaged. According to our Database, She has no children.
| Family |
| Parents |
Not Available |
| Husband |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Julia Levy Net Worth
Her net worth has been growing significantly in 2023-2024. So, how much is Julia Levy worth at the age of 89 years old? Julia Levy’s income source is mostly from being a successful educator. She is from Singapore. We have estimated Julia Levy's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
educator |
Julia Levy Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
Julia Levy (born May 15, 1934) is a Canadian microbiologist, immunologist, educator and entrepreneur.
The daughter of Guillaume Albert and Dorothy Frances Coppens, she was born Julia Coppens in Singapore.
In 1940, her father sent her mother and his two daughters from their home in Indonesia to Vancouver, British Columbia, where he joined them at the end of World War II after he was released from a Japanese prisoner of war camp.
Her early education was in Canada.
She studied immunology and bacteriology at the University of British Columbia, earning a BA in 1955.
Levy received a PhD in experimental pathology from the University of London in 1958.
In 1959, she returned to the University of British Columbia as an assistant professor, later becoming full professor.
Her research led her and her colleagues to participate in the development of photodynamic therapy (PDT) initially for treating cancer but more significantly as the first medical treatment of one of the leading causes of blindness among the elderly, age-related macular degeneration (AMD).
In the mid-1980s she and colleagues discovered the PDT agent, verteporfin, which QLT and its partner CIBA Vision (now Novartis Ophthalmalics) developed as Visudyne, a treatment for AMD.
Levy was named a fellow in the Royal Society of Canada in 1980, Pacific Canada Entrepreneur of the Year in 2000 and an Officer in the Order of Canada in 2001.
She has received the Future of Vision Award from the Foundation Fighting Blindness, the Helen Keller Award for Contributions to Vision and the Lifetime Achievement Award from the British Columbia Biotechnology Association.
She has also received a number of honorary doctorates from Canadian universities.
The Chemical Institute of Canada awards the Julia Levy Award for successful commercialization of innovation in the field of biomedical science and engineering.
She married Edwin Levy; the couple have two children.
In 1984, she joined the four founding members at biopharmaceutical company Quadra Logic Technologies (later QLT Inc.).
The PDT drug Photofrin was approved by the Canadian government for treatment of bladder cancer in 1993.
Subsequently, it has been approved in the United States and elsewhere for the treatment of several other types of cancer.
Initially Levy was Chief Scientific Officer of QLT, but from 1995 to 2001 she served as Chief Executive Officer and President of QLT.
Visudyne was approved by the US FDA in 2000 and throughout the world thereafter.
For ophthalmologists, this therapy added "a technique to their treatment armamentarium for some lesions for which there has been no other proven treatment."
As a result of the success of Visudyne, QLT became one of the 21% of biotechnology companies that were profitable in the year 2000.
She has expanded her methodology to treat HIV/AIDS, arthritis and age-related macular degeneration.
